AC
OXFD

Ascend Capital’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Ascend Capital’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-51,655
Closed -$868K – 268
2017
Q3 		$868K Buy
+51,655
New +$841K 0.03% 154

Other funds holding OXFD

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Ascend Capital's OXFD Position: Q4 2017 in Review

Ascend Capital sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q4 2017, closing a stake of 51,655 shares — an estimated $868K sold.

Ascend Capital first reported a position in OXFD in Q3 2017 and held it in 1 quarter. The position peaked at $868K in Q3 2017. 77 funds tracked by Wall St. Rank hold OXFD as of Q4 2017.

  • Ascend Capital reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Ascend Capital sold 51,655 Oxford Immunotec Global PLC Ordinary Shares shares in Q4 2017, an estimated $868K.
  • Ascend Capital first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q3 2017 and held it in 1 quarter.
  • Ascend Capital's Oxford Immunotec Global PLC Ordinary Shares position peaked at $868K in Q3 2017.
  • 77 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.